Prevenzione e gestione del diabete mellito post-trapianto

Translated title of the contribution: Prevention and management of post-transplant diabetes mellitus

Valeria Grancini, E. Orsi

Research output: Contribution to journalArticle

Abstract

The incidence of new-onset diabetes after transplant (NODAT) varies depending on the organ transplanted and the underlying disease, and in about 80% of cases it develops within three months after surgery. The disease is associated with an increased risk of organ rejection, infections, cardiovascular events and death. The need for immunosuppressive drugs such as glucocorticoids and calcineurin inhibitors is an important risk factor for the development of NODAT. Thorough pre-transplant screening is essential for the correct management of NODAT, and patients who develop diabetes mellitus (DM) must receive appropriate educational therapy. The stress of surgery and high doses of glucocorticoids in the immediate post-transplant period make insulin necessary from the early days in the majority of cases, but since no specific studies are available for the long-term management of NODAT the ADA guidelines for the treatment of type 2 DM are applied. When educational therapy fails to control glucose homeostasis, insulin is the most effective and safest drug for these patients. Metformin is not recommended as first-line drug for NODAT, but transplant is not an absolute contraindication to its use which, however, must be closely supervised. Studies to assess the efficacy and safety of incretins for patients with NODAT are currently in progress, but these drugs can lead to reduced intestinal motility, which could interfere with immunosuppressive therapy. Thiazolidinediones are not indicated in this population, predisposed to osteoporosis and at increased cardiovascular risk. Sulfonylureas are contraindicated too, particularly the molecules that can cause severe and prolonged hypoglycemia. In conclusion, when educational therapy fails to control NODAT adequately, the use of antidiabetic drugs - except insulin - is still under discussion, since no randomized controlled trials on their use in this population have been reported.

Original languageItalian
Pages (from-to)121-125
Number of pages5
JournalGiornale Italiano di Diabetologia e Metabolismo
Volume32
Issue number3
Publication statusPublished - 2012

Fingerprint

Diabetes Mellitus
Transplants
Insulin
Immunosuppressive Agents
Pharmaceutical Preparations
Glucocorticoids
Cardiovascular Infections
Incretins
Therapeutics
Thiazolidinediones
Gastrointestinal Motility
Metformin
Patient Safety
Hypoglycemia
Hypoglycemic Agents
Type 2 Diabetes Mellitus
Population
Osteoporosis
Homeostasis
Randomized Controlled Trials

ASJC Scopus subject areas

  • Endocrinology
  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Prevenzione e gestione del diabete mellito post-trapianto. / Grancini, Valeria; Orsi, E.

In: Giornale Italiano di Diabetologia e Metabolismo, Vol. 32, No. 3, 2012, p. 121-125.

Research output: Contribution to journalArticle

@article{9df7394de6fc4323b2ce28e4266d056d,
title = "Prevenzione e gestione del diabete mellito post-trapianto",
abstract = "The incidence of new-onset diabetes after transplant (NODAT) varies depending on the organ transplanted and the underlying disease, and in about 80{\%} of cases it develops within three months after surgery. The disease is associated with an increased risk of organ rejection, infections, cardiovascular events and death. The need for immunosuppressive drugs such as glucocorticoids and calcineurin inhibitors is an important risk factor for the development of NODAT. Thorough pre-transplant screening is essential for the correct management of NODAT, and patients who develop diabetes mellitus (DM) must receive appropriate educational therapy. The stress of surgery and high doses of glucocorticoids in the immediate post-transplant period make insulin necessary from the early days in the majority of cases, but since no specific studies are available for the long-term management of NODAT the ADA guidelines for the treatment of type 2 DM are applied. When educational therapy fails to control glucose homeostasis, insulin is the most effective and safest drug for these patients. Metformin is not recommended as first-line drug for NODAT, but transplant is not an absolute contraindication to its use which, however, must be closely supervised. Studies to assess the efficacy and safety of incretins for patients with NODAT are currently in progress, but these drugs can lead to reduced intestinal motility, which could interfere with immunosuppressive therapy. Thiazolidinediones are not indicated in this population, predisposed to osteoporosis and at increased cardiovascular risk. Sulfonylureas are contraindicated too, particularly the molecules that can cause severe and prolonged hypoglycemia. In conclusion, when educational therapy fails to control NODAT adequately, the use of antidiabetic drugs - except insulin - is still under discussion, since no randomized controlled trials on their use in this population have been reported.",
keywords = "Calcineurin inhibitors, Glucocorticoids, Incretins, Insulin, Metformin, New onset diabetes after transplant (NODAT)",
author = "Valeria Grancini and E. Orsi",
year = "2012",
language = "Italian",
volume = "32",
pages = "121--125",
journal = "Giornale Italiano di Diabetologia",
issn = "1593-6104",
publisher = "UTET Periodici Scientifici srl",
number = "3",

}

TY - JOUR

T1 - Prevenzione e gestione del diabete mellito post-trapianto

AU - Grancini, Valeria

AU - Orsi, E.

PY - 2012

Y1 - 2012

N2 - The incidence of new-onset diabetes after transplant (NODAT) varies depending on the organ transplanted and the underlying disease, and in about 80% of cases it develops within three months after surgery. The disease is associated with an increased risk of organ rejection, infections, cardiovascular events and death. The need for immunosuppressive drugs such as glucocorticoids and calcineurin inhibitors is an important risk factor for the development of NODAT. Thorough pre-transplant screening is essential for the correct management of NODAT, and patients who develop diabetes mellitus (DM) must receive appropriate educational therapy. The stress of surgery and high doses of glucocorticoids in the immediate post-transplant period make insulin necessary from the early days in the majority of cases, but since no specific studies are available for the long-term management of NODAT the ADA guidelines for the treatment of type 2 DM are applied. When educational therapy fails to control glucose homeostasis, insulin is the most effective and safest drug for these patients. Metformin is not recommended as first-line drug for NODAT, but transplant is not an absolute contraindication to its use which, however, must be closely supervised. Studies to assess the efficacy and safety of incretins for patients with NODAT are currently in progress, but these drugs can lead to reduced intestinal motility, which could interfere with immunosuppressive therapy. Thiazolidinediones are not indicated in this population, predisposed to osteoporosis and at increased cardiovascular risk. Sulfonylureas are contraindicated too, particularly the molecules that can cause severe and prolonged hypoglycemia. In conclusion, when educational therapy fails to control NODAT adequately, the use of antidiabetic drugs - except insulin - is still under discussion, since no randomized controlled trials on their use in this population have been reported.

AB - The incidence of new-onset diabetes after transplant (NODAT) varies depending on the organ transplanted and the underlying disease, and in about 80% of cases it develops within three months after surgery. The disease is associated with an increased risk of organ rejection, infections, cardiovascular events and death. The need for immunosuppressive drugs such as glucocorticoids and calcineurin inhibitors is an important risk factor for the development of NODAT. Thorough pre-transplant screening is essential for the correct management of NODAT, and patients who develop diabetes mellitus (DM) must receive appropriate educational therapy. The stress of surgery and high doses of glucocorticoids in the immediate post-transplant period make insulin necessary from the early days in the majority of cases, but since no specific studies are available for the long-term management of NODAT the ADA guidelines for the treatment of type 2 DM are applied. When educational therapy fails to control glucose homeostasis, insulin is the most effective and safest drug for these patients. Metformin is not recommended as first-line drug for NODAT, but transplant is not an absolute contraindication to its use which, however, must be closely supervised. Studies to assess the efficacy and safety of incretins for patients with NODAT are currently in progress, but these drugs can lead to reduced intestinal motility, which could interfere with immunosuppressive therapy. Thiazolidinediones are not indicated in this population, predisposed to osteoporosis and at increased cardiovascular risk. Sulfonylureas are contraindicated too, particularly the molecules that can cause severe and prolonged hypoglycemia. In conclusion, when educational therapy fails to control NODAT adequately, the use of antidiabetic drugs - except insulin - is still under discussion, since no randomized controlled trials on their use in this population have been reported.

KW - Calcineurin inhibitors

KW - Glucocorticoids

KW - Incretins

KW - Insulin

KW - Metformin

KW - New onset diabetes after transplant (NODAT)

UR - http://www.scopus.com/inward/record.url?scp=84866358376&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866358376&partnerID=8YFLogxK

M3 - Articolo

VL - 32

SP - 121

EP - 125

JO - Giornale Italiano di Diabetologia

JF - Giornale Italiano di Diabetologia

SN - 1593-6104

IS - 3

ER -